

Gnt  
A2  
12. (New) A method of treating or preventing metastasis in a mammal, including a human, comprising administering the alkylating anthracycline of formula Ia or Ib as claimed in Claim 1 and an antineoplastic topoisomerase II inhibitor.


13. (New) A method of treating a tumor in a mammal, including a human, by inhibiting angiogenesis comprising administering the alkylating anthracycline of formula Ia or Ib as claimed in Claim 1 and an antineoplastic topoisomerase II inhibitor.

#### REMARKS

Claims 1-6 and 10-13 are active in the present application. Claims 1-4 have been amended to remove multiple dependencies and for clarity. Claims 10-13 are new claims. Support for new claims is found in the original claims and in the specification, for example on page 2, line 20-26 and page 4, lines 9-19. No new matter is added. An action on the merits and allowance of the claims is solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

  
Norman F. Oblon  
Attorney of Record  
Registration No. 24,618

Daniel J. Pereira, Ph.D.  
Registration No. 45,518



**22850**

(703) 413-3000  
Fax #: (703) 413-2220  
NFO/DJP/law

I:\atty\SUKOS\212136-PR.WPD

**Marked-Up Copy**

Serial No:



Amendment Filed on: 08/22/01

IN THE CLAIMS

Claims 7-9 - (Cancelled).

Please amend the claims as follows.

--1. (Amended) [Products containing] A product comprising an alkylating anthracycline of formula Ia or Ib:



and an antineoplastic topoisomerase II inhibitor as a combined preparation for simultaneous, separate or sequential use in the treatment of tumors.

2. [Products] The product according to claim 1 wherein the alkylating anthracycline is 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methanesulfonyl daunorubicin.

4. [Products] The product according to claim 1 [or 2] wherein the topoisomerase II inhibitor is doxorubicin.--

[illegible]